The order of cancer-driving mutations—genetic changes—plays an important role in whether tumors in the intestine can develop, ...
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S.
Proceedings of the National Academy of Sciences of the United States of America, Vol. 87, No. 23 (Dec., 1990), pp. 9103-9107 (5 pages) Avian c-erbB is activated to a leukemia oncogene following ...
Incyte (INCY) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy designation to INCA033989, a ...
Role of chest radiation in extensive-stage small cell lung cancer with ipsilateral pleural effusion. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not ...
Checkpoint kinase 2, or CHEK2, for short, is a gene that normally helps with DNA repair. If you have a mutation, or variation, in this gene, you may be at an increased risk for developing cancer. The ...
A newly discovered genetic mutation unique to humans may help explain why we are significantly more vulnerable to cancer than our closest evolutionary relatives. Researchers at the University of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results